Drug intelligence / Profile preview

Tomokast

Development stage: Unknown
Lead developer: RANTOMO Life Sciences Bharat
Modality: Small Molecules
Administration: Oral

Overview

**Tomokast** is an oral fixed-dose anti-allergy tablet marketed by Rantomo Life Sciences. Each tablet contains levocetirizine 5 mg and montelukast 10 mg. Levocetirizine inhibits histamine H1 receptor signaling to reduce histamine-mediated symptoms such as sneezing, rhinorrhea, and watery eyes, while montelukast antagonizes cysteinyl leukotriene receptor 1 to reduce leukotriene-driven allergic inflammation. It is marketed for relief of allergic conditions, particularly allergic rhinitis. ([rantomo.com](https://www.rantomo.com/tomokast))

Brand names: Tomokast
Other names: levocetirizine + montelukast

Targets

HRH1 (Histamine H1 Receptor)CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)

Beyond the preview

Go deeper on Tomokast.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tomokast.

Explore the full profile